1 – 13 of 13
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
(
- Contribution to journal › Article
- 2016
-
Mark
SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.
2016) In Leukemia & Lymphoma(
- Contribution to journal › Article
-
Mark
Single nucleotide polymorphism array analysis of clonal evolution in younger adult acute lymphoblastic leukemia
(
- Contribution to journal › Article
- 2011
-
Mark
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
(
- Contribution to journal › Article
-
Mark
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article
-
Mark
Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.
(
- Contribution to journal › Article
-
Mark
Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
(
- Contribution to journal › Article
-
Mark
'Hairy' cells: where are the roots of this leukemia?
(
- Contribution to journal › Article
- 2010
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.
(
- Contribution to journal › Article
-
Mark
Clonal evolution to histiocytic sarcoma with the BCR/ABL rearrangement 14 years after acute lymphoblastic leukemia.
(
- Contribution to journal › Letter
- 2008
-
Mark
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia
(
- Contribution to journal › Article